Facebook Pixel Code
About Sickkids
About SickKids

Daniel Morgenstern, MD

The Hospital for Sick Children
Staff Physician, Solid Tumour Section

Director, New Agent and Innovative Therapy Program (NAIT)

Director, Therapeutic MIBG Program

Research Institute
Associate Scientist
Translational Medicine

University of Toronto
Department of Paediatrics
Assistant Professor

Phone: 416-813-7654 x 227565
Fax: 416-813-5327
Email: daniel.morgenstern@sickkids.ca
Alternate Contact: Catherine Lim-Shue
Alternate Phone: 416-813-7654 ext. 228454
Alternate Email: catherine.limshue@sickkids.ca

Brief Biography

Dr. Morgenstern undertook his undergraduate medical training at the University of Cambridge (UK) and graduated in 2001 with combined PhD and MB BChir degrees. He then completed paediatric training at University College London Hospital and subspecialty training in paediatric oncology at Great Ormond Street Hospital for Children in London. He qualified for membership of the Royal College of Paediatrics and Child Health in 2005 and received his Certificate of Completion of Specialist Training (CCST) in paediatrics and paediatric oncology in 2011. He was an academic clinical lecturer based at UCL Institute of Child Health and undertook research relating to cancer immunology. Morgenstern subsequently undertook a fellowship in drug development at the Royal Marsden Hospital, Sutton, UK and then moved to SickKids as the first Sears Foundation / Garron Cancer Centre Fellow in Neuroblastoma in 2012.

In 2013, Morgenstern moved back to the UK to take up a role as consultant in paediatric oncology at Great Ormond Street Hospital and Honorary Senior Lecturer at UCL Institute of Child Health, where he was clinical lead for neuroblastoma and for the autograft program. He was also Chair of the UK Children’s Cancer and Leukemia Group (CCLG), Neuroblastoma Special Interest Group and an active member of SIOPEN, the European collaborative group for neuroblastoma research. He remains a member of the UK National Paediatric Autograft Panel.

Dr. Morgenstern returned to SickKids in September 2016 as Staff Oncologist and Director of the New Agent and Innovative Therapies (NAIT) program. 

Academic Background

Undergraduate training and PhD
University of Cambridge, 1993-2001

Paediatric training
University College London Hospitals, 2002-2007

Higher specialist training in paediatric oncology and academic clinical lecturer
Great Ormond Street Hospital and UCL Institute of Child Health, 2007-11

Clinical Care Activities

Morgenstern’s clinical activities are focused on the care of children with solid tumours and in particular neuroblastoma. He is responsible for the therapeutic MIBG program, a type of targeted radiotherapy specific for neuroblastoma.  He also leads the New Agent and Innovative Therapies (NAIT) program, managing a portfolio of more than 20 oncology early phase clinical trials.

Research Interests

  • Novel therapies and clinical trials for high-risk neuroblastoma.
  • Early phase clinical trials.
  • Use of immune checkpoint inhibitors and immunotherapy for hypermutant childhood cancers


Brigid Leventhal Merit Award, American Society of Clinical Oncology, 2013.


For full list of publications, please see PubMed.